Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CYH33 (Risovalisib) in Advanced Solid Tumors
NCT03544905Phase 1Completed
- Sponsor
- Haihe
- Start
- Jul 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of risovalisib mesylate in solid tumor (advanced stage), breast cancer, ovarian cancer and 6 more, sponsored by Haihe. Primary endpoint: Maximum Tolerated Dose at 35 days. Started Jul 2018; status: completed.
02
Drugs
risovalisib mesylate
03
Conditions
solid tumor (advanced stage)breast cancerovarian cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03544905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03544905.